Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Inclusion Criteria: * IIIA NSCLC patients according to TMN-staging of Lung Staging Standard version 7 2009, confirmed by histopathology or cytology after radical operation, and having EGFR exon 19 deletion mutation or exon 21 L858R single base substitution; * Accept study adjuvant therapy within 6 weeks post radical operation; * ECOP PS 0-1; Life expectancy ≥12 weeks; * Hematology: absolute neutrophil count (ANC) ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin concentration ≥ 9.0 g/dL (permit to maintain hematologic criteria by blood transfusion); * Liver Function: TBil ≤1.5xULN; ALT and AST ≤2.5xULN; * Renal Function: Cr ≤1.25xULN, and Ccr ≥60ml/min; * Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days before study treatment; * Signed inform consent form by patient or his/her legal representative; * Comply with study protocol and procedure, and be able to take oral medication; Aged ≥18 years and ≦75 years; * Eligible patients of reproductive potential (both sexes) must agree to use a reliable method of birth control before enrollment, during the study period and for at least 30 days after their last dose of study therapy; Exclusion Criteria: * Having treated by Her-Target therapy, i.e. erlotinib, gefitinib, cetuximab, trastuzumab; * Having treated by any systemic anti-tumor therapy of NSCLC, including cytotoxic therapy, target medication treatment (i.e. monoclonal antibody), investigational therapy; * Having local radiotherapy of NSCLC; Upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer; * The findings in radical operation are lymph nodes with extracapsular invasion, or fusion, or all of dissection lymph nodes positive by pathology; * Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival,cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor); * Confirmed recurrent cancer by Clinical objective evidence (pathology or radiography images) before the study adjuvant therapy; * Known hypersensitivity to platinum, Vinorelbine, EGFR-TKI agents or relevant components in the formulation; * Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection; * Active interstitial lung disease (ILD) by any clinical evidence; patients with any co-morbidities, or motalic disorders, or any abnormal findings in physical examination or laboratory tests are suspected to have contraindication of study therapy or high risk of study treatment complications; * Any unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, angina starting in latest 3 months, Congestive heart failure (NYHA ≥ II), myocardial infarction within 6 months prior enrollment, under medication treatment of severe arrhythmia, liver, renal or metabolic disease; * know HIV infection Pregnant or breastfeeding women; * ECOG PS ≥2; * Mixed with small cell lung cancer; * Other conditions investigators evaluate that patient is not eligible to this study.